Recently by Lori M. Waldron
Life Sciences
Life Sciences: Protecting the Crown Jewels - Important Strategies for Licensors of Intellectual Property
An innovator or owner of patent rights or other technology in the life sciences arena is often unable, because of lack of financial or other resources, to develop or commercialize a pharmaceutical product covered by such intellectual property rights. In these cases, the innovator/owner (the...
Read MoreBiotechnology | Life Sciences
Funding Biotech Innovation: The Ins And Outs Of Collaboration Arrangements And Licensing Agreements
Editor: Please describe your background and practice. Waldron: I am a transactional lawyer and a member of my firm’s Life Sciences Practice Group. My practice focuses on the representation of both emerging and well-established companies in business transactions, with a particular emphasis...
Read MoreHealthcare | Life Sciences
Buyer Beware: Important “Supply” Issues For Life Science Companies
Very often, a biotech or other life sciences company will need to purchase materials or products from a third party vendor. This arrangement could be in connection with the company’s clinical testing/R&D or in connection with the company’s commercial supply of its product. In any...
Read MoreContracts
Five Traps For The Unwary Licensee
Licensors and licensees enter into agreements with each other all the time with respect to the commercialization of products covered by patent rights or other technology. These agreements can take many forms, including “pure” license grants, R&D collaborations and joint venture...
Read MoreHealthcare | Life Sciences
Six Important Strategies To Reduce The Royalty Burden For A Pharmaceutical Product
A biotech or pharmaceutical company will often need to in-license certain inventions in order to develop and commercialize its products. The company will most likely be required to pay to its licensor a royalty based on sales of its products (licensed products) that exploit the licensed...
Read More